- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06064097
- Oryginalna próba
Badanie z zastosowaniem nowego leku, niwolumabu, w skojarzeniu z lekami do chemioterapii w leczeniu rodzaju nowotworu zwanego rakiem nosogardzieli (NPC)
Badanie II fazy z zastosowaniem chemioimmunoterapii z gemcytabiną, cisplatyną i niwolumabem w leczeniu nowo zdiagnozowanego raka nosogardzieli (NPC)
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
- Inny: Quality-of-Life Assessment
- Lek: Cisplatin
- Procedura: Biospecimen Collection
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Inny: Questionnaire Administration
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Procedura: Positron Emission Tomography
- Biologiczny: Nivolumab
- Lek: Gemcitabine
- Procedura: Biopsy Procedure
- Procedura: Chest Radiography
- Inny: Electronic Health Record Review
- Promieniowanie: Radiation Therapy
- Inny: Fluciclovine F18
- Procedura: X-Ray Imaging
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor and blood) for future research studies.
X. To compare dental x-rays in patients prior to radiation and 1 year post radiation to evaluate for dental caries and bone health.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy and blood sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- Rekrutacyjny
- John Hunter Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: (02) 4985 5180
-
Główny śledczy:
- Kristy McCarthy
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrutacyjny
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 403-220-6898
- E-mail: research4kids@ucalgary.ca
-
Główny śledczy:
- Victor A. Lewis
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutacyjny
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Główny śledczy:
- Sarah J. McKillop
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrutacyjny
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 416-813-7654
- E-mail: ask.CRS@sickkids.ca
-
Główny śledczy:
- Avram E. Denburg
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Rekrutacyjny
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Numer telefonu: 514-412-4445
- E-mail: info@thechildren.com
-
Główny śledczy:
- Stephanie Mourad
-
Montreal, Quebec, Kanada, H3T 1C5
- Rekrutacyjny
- Centre Hospitalier Universitaire Sainte-Justine
-
Główny śledczy:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Numer telefonu: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutacyjny
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Numer telefonu: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Główny śledczy:
- Stephanie Vairy
-
-
-
-
-
Christchurch, Nowa Zelandia, 8011
- Rekrutacyjny
- Christchurch Hospital
-
Główny śledczy:
- Tristan Pettit
-
Kontakt:
- Site Public Contact
- Numer telefonu: 03 364 0640
-
-
Auckland
-
Grafton, Auckland, Nowa Zelandia, 1145
- Rekrutacyjny
- Starship Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 0800 728 436
-
Główny śledczy:
- Leander D. Timothy
-
-
-
-
-
San Juan, Portoryko, 00926
- Rekrutacyjny
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 787-474-0333
-
Główny śledczy:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- Rekrutacyjny
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Numer telefonu: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Główny śledczy:
- Jamie M. Aye
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85016
- Rekrutacyjny
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 602-546-0920
-
Główny śledczy:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72202-3591
- Rekrutacyjny
- Arkansas Children's Hospital
-
Główny śledczy:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Numer telefonu: 501-364-7373
-
-
California
-
Downey, California, Stany Zjednoczone, 90242
- Rekrutacyjny
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 626-564-3455
-
Główny śledczy:
- Robert M. Cooper
-
Loma Linda, California, Stany Zjednoczone, 92354
- Rekrutacyjny
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 909-558-4050
-
Główny śledczy:
- Albert Kheradpour
-
Los Angeles, California, Stany Zjednoczone, 90027
- Rekrutacyjny
- Children's Hospital Los Angeles
-
Główny śledczy:
- Rachana Shah
-
Kontakt:
- Site Public Contact
- Numer telefonu: 323-361-4110
-
Madera, California, Stany Zjednoczone, 93636
- Rekrutacyjny
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Główny śledczy:
- Ruetima Titapiwatanakun
-
Oakland, California, Stany Zjednoczone, 94611
- Rekrutacyjny
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-642-4691
- E-mail: Kpoct@kp.org
-
Główny śledczy:
- Aarati V. Rao
-
Oakland, California, Stany Zjednoczone, 94609
- Rekrutacyjny
- UCSF Benioff Children's Hospital Oakland
-
Główny śledczy:
- Jennifer G. Michlitsch
-
Kontakt:
- Site Public Contact
- Numer telefonu: 510-428-3264
- E-mail: PedOncRschOAK@ucsf.edu
-
San Diego, California, Stany Zjednoczone, 92123
- Rekrutacyjny
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Numer telefonu: 858-966-5934
-
Główny śledczy:
- William D. Roberts
-
San Francisco, California, Stany Zjednoczone, 94158
- Rekrutacyjny
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Główny śledczy:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Children's Hospital Colorado
-
Główny śledczy:
- Navin R. Pinto
-
Kontakt:
- Site Public Contact
- Numer telefonu: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06106
- Rekrutacyjny
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 860-545-9981
-
Główny śledczy:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Stany Zjednoczone, 19803
- Rekrutacyjny
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- Children's National Medical Center
-
Główny śledczy:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Numer telefonu: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone, 32610
- Rekrutacyjny
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Numer telefonu: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Główny śledczy:
- Brian Stover
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Rekrutacyjny
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Sridhi Patel
-
Miami, Florida, Stany Zjednoczone, 33155
- Rekrutacyjny
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 888-624-2778
-
Główny śledczy:
- Ziad A. Khatib
-
Orlando, Florida, Stany Zjednoczone, 32806
- Rekrutacyjny
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Główny śledczy:
- Zhongbo Hu
-
Orlando, Florida, Stany Zjednoczone, 32827
- Rekrutacyjny
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Sridhi Patel
-
Pensacola, Florida, Stany Zjednoczone, 32504
- Rekrutacyjny
- Nemours Children's Clinic - Pensacola
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Główny śledczy:
- Jeffrey H. Schwartz
-
Tampa, Florida, Stany Zjednoczone, 33607
- Rekrutacyjny
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Kontakt:
- Site Public Contact
- Numer telefonu: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Główny śledczy:
- Don E. Eslin
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30329
- Rekrutacyjny
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Główny śledczy:
- Sarah G. Mitchell
-
Kontakt:
- Site Public Contact
- Numer telefonu: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Rekrutacyjny
- Lurie Children's Hospital-Chicago
-
Główny śledczy:
- Amy L. Walz
-
Kontakt:
- Site Public Contact
- Numer telefonu: 773-880-4562
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Zawieszony
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Rekrutacyjny
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-248-1199
-
Główny śledczy:
- Marissa Just
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- Jeszcze nie rekrutacja
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 859-257-3379
-
Główny śledczy:
- James T. Badgett
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70118
- Rekrutacyjny
- Children's Hospital New Orleans
-
Główny śledczy:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 504-894-5377
-
-
Maine
-
Scarborough, Maine, Stany Zjednoczone, 04074
- Rekrutacyjny
- Maine Children's Cancer Program
-
Główny śledczy:
- Aaron R. Weiss
-
Kontakt:
- Site Public Contact
- Numer telefonu: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Rekrutacyjny
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Główny śledczy:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Rekrutacyjny
- Dana-Farber Cancer Institute
-
Główny śledczy:
- Allison F. O'Neill
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-442-3324
-
-
Michigan
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Rekrutacyjny
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Główny śledczy:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Rekrutacyjny
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Numer telefonu: 855-776-0015
-
Główny śledczy:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- Rekrutacyjny
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 601-815-6700
-
Główny śledczy:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64108
- Rekrutacyjny
- Children's Mercy Hospitals and Clinics
-
Główny śledczy:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Numer telefonu: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Główny śledczy:
- Frederick S. Huang
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Rekrutacyjny
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Numer telefonu: 402-955-3949
-
Główny śledczy:
- Jill C. Beck
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- Rekrutacyjny
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Główny śledczy:
- Jill C. Beck
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Rekrutacyjny
- Hackensack University Medical Center
-
Główny śledczy:
- Katharine Offer
-
Kontakt:
- Site Public Contact
- Numer telefonu: 551-996-2897
-
Neptune City, New Jersey, Stany Zjednoczone, 07753
- Rekrutacyjny
- Jersey Shore Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-776-4240
-
Główny śledczy:
- Katharine Offer
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Główny śledczy:
- Scott Moerdler
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-235-8675
-
Newark, New Jersey, Stany Zjednoczone, 07112
- Rekrutacyjny
- Newark Beth Israel Medical Center
-
Główny śledczy:
- Scott Moerdler
-
Kontakt:
- Site Public Contact
- Numer telefonu: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Główny śledczy:
- Teena Bhatla
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12208
- Rekrutacyjny
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 518-262-5513
-
Główny śledczy:
- Lauren R. Weintraub
-
The Bronx, New York, Stany Zjednoczone, 10467
- Rekrutacyjny
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Numer telefonu: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Główny śledczy:
- Alice Lee
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Rekrutacyjny
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-804-9376
-
Główny śledczy:
- Joel A. Kaplan
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke University Medical Center
-
Główny śledczy:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Numer telefonu: 888-275-3853
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- Rekrutacyjny
- East Carolina University
-
Kontakt:
- Site Public Contact
- Numer telefonu: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Główny śledczy:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Rekrutacyjny
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Numer telefonu: 336-713-6771
-
Główny śledczy:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Rekrutacyjny
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Główny śledczy:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Rekrutacyjny
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 513-636-2799
- E-mail: cancer@cchmc.org
-
Główny śledczy:
- Brian K. Turpin
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Rekrutacyjny
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 216-844-5437
-
Główny śledczy:
- Duncan S. Stearns
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Rekrutacyjny
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Główny śledczy:
- Mark A. Ranalli
-
Dayton, Ohio, Stany Zjednoczone, 45404
- Rekrutacyjny
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-228-4055
-
Główny śledczy:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- Rekrutacyjny
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Główny śledczy:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stany Zjednoczone, 18103
- Rekrutacyjny
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Numer telefonu: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Główny śledczy:
- Jacob A. Troutman
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Rekrutacyjny
- Penn State Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 717-531-6012
-
Główny śledczy:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Rekrutacyjny
- Children's Hospital of Philadelphia
-
Kontakt:
- Site Public Contact
- Numer telefonu: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Główny śledczy:
- Theodore W. Laetsch
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15224
- Rekrutacyjny
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Numer telefonu: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Główny śledczy:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29203
- Rekrutacyjny
- Prisma Health Richland Hospital
-
Główny śledczy:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Numer telefonu: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Rekrutacyjny
- BI-LO Charities Children's Cancer Center
-
Główny śledczy:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Numer telefonu: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Rekrutacyjny
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Numer telefonu: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Główny śledczy:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38105
- Rekrutacyjny
- Saint Jude Children's Research Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 888-226-4343
- E-mail: referralinfo@stjude.org
-
Główny śledczy:
- Catherine G. Lam
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-811-8480
-
Główny śledczy:
- Scott C. Borinstein
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Numer telefonu: 615-342-1919
-
Główny śledczy:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78723
- Rekrutacyjny
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Główny śledczy:
- Shannon M. Cohn
-
Dallas, Texas, Stany Zjednoczone, 75390
- Rekrutacyjny
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Główny śledczy:
- Avanthi T. Shah
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Rekrutacyjny
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Główny śledczy:
- Chelsee Greer
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 713-798-1354
- E-mail: burton@bcm.edu
-
Główny śledczy:
- Mehmet F. Okcu
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Główny śledczy:
- Najat C. Daw
-
San Antonio, Texas, Stany Zjednoczone, 78207
- Rekrutacyjny
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Numer telefonu: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Główny śledczy:
- Julie Voeller
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- Rekrutacyjny
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Główny śledczy:
- Brian C. Belyea
-
Norfolk, Virginia, Stany Zjednoczone, 23507
- Rekrutacyjny
- Children's Hospital of The King's Daughters
-
Kontakt:
- Site Public Contact
- Numer telefonu: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Główny śledczy:
- Melissa S. Mark
-
Richmond, Virginia, Stany Zjednoczone, 23298
- Rekrutacyjny
- VCU Massey Comprehensive Cancer Center
-
Główny śledczy:
- Madhu S. Gowda
-
Kontakt:
- Site Public Contact
- Numer telefonu: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98105
- Rekrutacyjny
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-987-2000
-
Główny śledczy:
- Sarah E. Leary
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Rekrutacyjny
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 253-403-1461
- E-mail: research@multicare.org
-
Główny śledczy:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Rekrutacyjny
- Children's Hospital of Wisconsin
-
Główny śledczy:
- Angela Steineck
-
Kontakt:
- Site Public Contact
- Numer telefonu: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) (8th edition) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
- to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female)
- to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) â ¥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
Inne nazwy:
Given IV
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Undergo ECHO
Inne nazwy:
Undergo MUGA
Inne nazwy:
Undergo PET
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo tissue biopsy
Inne nazwy:
Undergo chest x-ray
Inne nazwy:
Ancillary studies Receive radiation therapy
Inne nazwy:
Given IV
Inne nazwy:
Undergo dental x-ray
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
Ramy czasowe: Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events (8th edition). IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Event-free survival (EFS)
Ramy czasowe: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
Ramy czasowe: At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
Ramy czasowe: At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
Ramy czasowe: Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
EFS
Ramy czasowe: At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
Ramy czasowe: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
Ramy czasowe: At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
Ramy czasowe: Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
Ramy czasowe: Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
Ramy czasowe: Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
Ramy czasowe: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
Ramy czasowe: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
Ramy czasowe: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
|
Dental changes
Ramy czasowe: At baseline (prior to radiation) and up to 1 post radiation
|
Will include dental caries and osteoradionecrosis. Dental caries will be quantified as the number of teeth with caries, and bone health will be evaluated as a categorical variable using 0 for no disease and a score of 1-4 to match stage of periodontal disease as described in 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was co-presented by the American Academy of Periodontology and the European Federation of Periodontology staging framework. Changes over time will be evaluated using paired analyses. Given the small sample size, results will primarily be descriptive, with patient's dental caries and bone health data summarized using descriptive statistics. |
At baseline (prior to radiation) and up to 1 post radiation
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Robyn D Gartrell, Children's Oncology Group
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Stomatognatyczne
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Rak
- Choroby otorynolaryngologiczne
- Nowotwory gardła
- Nowotwory otorynolaryngologiczne
- Choroby jamy nosowo-gardłowej
- Choroby gardła
- Nowotwory jamy nosowo-gardłowej
- Rak jamy nosowo-gardłowej
- Aminokwasy, peptydy i białka
- Białka
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Techniki śledcze
- Lecznictwo
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Techniki cytologiczne
- Cytodiagnoza
- Zjawiska fizyczne
- Sprzęt i materiały eksploatacyjne
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Chemikalia nieorganiczne
- Związki chloru
- Związki azotu
- Deoksycytydyna
- Cytydyna
- Nukleozydy pirymidynowe
- Pirymidyn
- Elementy
- Metale
- Techniki diagnostyczne, chirurgiczne
- Techniki chemii, analityczne
- Analiza widma
- Metale, ciężkie
- Związki platynowe
- Zjawiska elektromagnetyczne
- Zjawiska magnetyczne
- Elementy przejściowe
- Promieniowanie elektromagnetyczne
- Promieniowanie, jonizujące
- Niwolumab
- Gemcytabina
- Cisplatyna
- Cytrynian 1,2-diaminocykloheksanoplatyny II
- Radioterapia
- Promieniowanie
- Biopsja
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Platyna
- Promieniowanie rentgenowskie
- Phantoms, obrazowanie
- Flucyklowiina F-18
Inne numery identyfikacyjne badania
- NCI-2023-07208
- U10CA180886 (Grant/umowa NIH USA)
- NCI-2023-07208 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- ARAR2221 (Inny identyfikator: CTEP)
- ARAR2221 (Inny identyfikator: Children's Oncology Group)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .